• HSD65 Investing in Diagnosis: Health Economic Value of Early Obstructive Sleep Apnea Detection for Private Insurers in India

    Dec 1, 2025, 00:00

  • HPR167 Publicly Funded Fertility Preservation Services for Medical Reasons in Selected Countries

    Dec 1, 2025, 00:00

  • CO185 Preliminary Real-World Comparative Analysis of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in Second-Line HER2-Positive Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • EPH101 Experience of Pediatric Dental Screening in Hungary and in National Minority Groups in Romania

    Dec 1, 2025, 00:00

  • HPR22 Analysis of ATC Equivalent Group and Therapeutic Reference Code Distributions Based on Drug Price and Reimbursement Lists in Türkiye Between 2020 and 2025

    Dec 1, 2025, 00:00

  • CO230 Systematic Review of Prognostic Factors and Treatment Effect Modifiers for Transthyretin Amyloid Cardiomyopathy

    Dec 1, 2025, 00:00

  • MSR222 What Prompt Engineering Missed and How Context Engineering Fixes It

    Dec 1, 2025, 00:00

  • PCR170 Patient and Societal Preferences for On-Demand Treatment in Hereditary Angioedema: Estimation of Utility Using a Discrete Choice Experiment

    Dec 1, 2025, 00:00

  • MSR99 Evaluation of the Measurement Properties of the German LupusPRO™ for Swiss-German SLE Patients

    Dec 1, 2025, 00:00

  • EE52 Analysis of the Fiscal and Socioeconomic Impact of a National Social Program to Support In Vitro Fertilization in Romania: A Generational Accounting Model

    Dec 1, 2025, 00:00

  • MSR91 Evaluating Bayesian Borrowing Methods for Treatment Effect Extrapolation: A Simulation-Based Study

    Dec 1, 2025, 00:00

  • CO104 Evaluating the Effectiveness of FitterLife: A Community-Based Virtual Weight Management Program for Overweight Adults Without Diabetes or Hypertension in Singapore

    Dec 1, 2025, 00:00

  • EPH245 The Incidence Mortality and Survival of Malignant Chondrosarcoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • EE455 Exploratory Assessment of the Societal Impact of Changing Informal Care Hours in the Netherlands

    Dec 1, 2025, 00:00

  • EPH249 The Incidence, Mortality, and Survival of Nonmetastatic Colorectal Cancer (CRC) per TNM Stages in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • RWD138 Primary Expenditure Drivers and Future Challenges From Emerging Technologies in Brazilian Private Market Real-World Data Analysis From a Brazilian Employer-Sponsored, Self-Insured Health Plan

    Dec 1, 2025, 00:00

  • P55 Choosing Appropriate Population-Adjusted Indirect Comparison Methods for Health Technology Assessment: A Simulation Study on the Impact of Effect Modifiers Baseline Imbalances and Sample Size

    Dec 1, 2025, 00:00

  • CO246 The Prevalence of COAs and DHTs for Studying Sleep Disorders in Clinical Trials

    Dec 1, 2025, 00:00

  • HTA11 A NICE Idea? Assessing the Impact of the Severity Modifier in Oncology and Nononcology Single Technology Appraisals

    Dec 1, 2025, 00:00

  • CO127 Health Gains Associated With Homologous Recombination Deficiency Testing for Ovarian Cancer in South Korea: A Model-Based Analysis

    Dec 1, 2025, 00:00

  • HSD33 Differential Impact of Type 1 and Type 2 Diabetes on Families: A UK Cross-Sectional Study Using FROM-16

    Dec 1, 2025, 00:00

  • HTA13 A Review of Cost Comparisons Submitted to NICE Since the Introduction of the Proportional Approach to Technology Appraisal

    Dec 1, 2025, 00:00

  • P9 Exploring Variability in EQ VAS Scores: A Systematic Review and Meta-Regression of Population Health Studies

    Dec 1, 2025, 00:00

  • HTA157 From the Outside Looking in: Patient Advocacy Groups' and Healthcare Providers' Perspectives on Patient Engagement Strategies in the Israeli Health Technology Assessment Process

    Dec 1, 2025, 00:00

  • MSR187 Simulation-Guided Trial Planning of a Cluster Randomized Trial With Probabilistic Covariate-Constrained Randomization for Vaccine Coverage

    Dec 1, 2025, 00:00

  • PCR258 Use of EORTC Item Lists for Patient-Reported Outcome Measurement in Industry-Sponsored Research: A Three-Year Snapshot of Study Characteristics

    Dec 1, 2025, 00:00

  • MT2 Adoption of AI Clinical Decision Support Systems in Primary Care: An Evaluation of Physician Acceptance

    Dec 1, 2025, 00:00

  • MSR16 Advancing the Science of Qualitative Patient Preference Assessment Using Large Language Models

    Dec 1, 2025, 00:00

  • HPR225 Trends in EMA-Approved New Medicines 2015-2024: New Mechanisms of Action and Regulatory Shifts

    Dec 1, 2025, 00:00

  • EPH223 Survey of Depression Literacy and Help-Seeking Behavior Among Secondary School Students

    Dec 1, 2025, 00:00

  • P28 Survival Time-Adjusted Indirect Comparisons: A New Methodology for Comparing Between Phases of Treatment in Early Cancer

    Dec 1, 2025, 00:00

  • HPR59 Divergent Biologic Price Archetypes: Year-on-Year List Price Evolution Pre- and Post-Biosimilar Entry in the US, Europe, and Japan

    Dec 1, 2025, 00:00

  • EE594 NCFBE Hospitalizations Costs Across Different Healthcare Systems: Insights From England and France in 2022 Using PMSI and HES Databases

    Dec 1, 2025, 00:00

  • PCR118 Health-Related Quality of Life in Patients With Metastatic Urothelial Cancer: Results of a Cross-Sectional Survey in Europe

    Dec 1, 2025, 00:00

  • EPH58 Detection of a Potential Pericarditis Safety Signal Associated With Azithromycin: Evidence From FAERS Disproportionality Analysis

    Dec 1, 2025, 00:00

  • CO239 The Effect of Nutritional Supplements on Semen Quality and Pregnancy Rates in Patients With Male Factor Infertility: A Systematic Literature Review and Network Meta-Analysis

    Dec 1, 2025, 00:00

  • EE389 Economic Evaluation of the Breast Thermal Activity Indicator Plus Clinical Breast Examination

    Dec 1, 2025, 00:00

  • CO214 Robotic-Assisted Surgery Using the Da Vinci Surgical System in a Nordic Population: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • CO216 Safety and Efficacy of Antibody Drug Conjugate (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Triple-Negative Breast Cancer (TNBC): Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HPR21 An Analysis of Possible Reference Countries for a US Most-Favored Nation Policy and Implications of Differences in Cost of Living on Global Drug Pricing Policies

    Dec 1, 2025, 00:00

  • HTA2 A Comparative Analysis of Reimbursement Decisions for Targeted Therapies and Immunotherapies in NSCLC Across EU HTA Bodies

    Dec 1, 2025, 00:00

  • HTA221 Life-Cycle Stage-Specific Prioritization of Joint Clinical Assessment PICOs: Balancing Access Potential Feasibility and Likelihood

    Dec 1, 2025, 00:00

  • EPH67 Economic and Epidemiological Burden of Type 1 Diabetes In France

    Dec 1, 2025, 00:00

  • SA19 Characterizing Exploratory Endpoints in Early Oncology Trials: Insights From Trial Registry Audit

    Dec 1, 2025, 00:00

  • HTA258 Nutrieconomics: Concept and Expert Consensus on Health Technology Assessment of Nutritional Interventions in Brazil

    Dec 1, 2025, 00:00

  • EE311 Cost-Utility Analysis of Transcatheter Valve Replacement Using Valves With RESILIA Tissue for the Treatment of Aortic Stenosis in South Korea

    Dec 1, 2025, 00:00

  • OP25 Understanding the Needs and Aspirations of Emerging HEOR Talent: Results From the ISPOR New Professional and Student Survey

    Dec 1, 2025, 00:00

  • MT33 Optimizing MASLD Diagnostic Protocols: A Microsimulation Analysis of Test Sensitivity Requirements

    Dec 1, 2025, 00:00

  • HTA241 Navigating Clinical Trial Design Under the EU Health Technology Assessment Regulation

    Dec 1, 2025, 00:00

  • EE516 Healthcare Resource Utilization and Time Burden in Patients With Myelodysplastic Syndromes/Neoplasms Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents

    Dec 1, 2025, 00:00

  • MSR80 Economic Valuation of Premature COVID-19 Mortality in Kuwait: A Comparative Analysis of Three Methodological Approaches

    Dec 1, 2025, 00:00

  • HTA61 Budget Impact Models in CEESP Opinions: A Decade of Insights

    Dec 1, 2025, 00:00

  • EE692 The Cost-Effectiveness of an Artificial Intelligence Software for Stroke Imaging and Treatment Decisions in NHS Hospitals

    Dec 1, 2025, 00:00

  • EE424 Estimating the Clinical and Economic Value of Aztreonam-Avibactam for the Treatment of Metallo-Beta-Lactamase–Producing Carbapenem- Resistant Enterobacterales Infections in China: Adopting the STEDI Value Framework

    Dec 1, 2025, 00:00

  • HPR188 Solving the PICO Puzzle: Perspectives on Outcome Measures for Oncology Medicines in Assessments of the European Medicines Agency and Health Technology Assessment Organizations in Europe

    Dec 1, 2025, 00:00

  • EE69 Assessment of the Economic and Societal Impact of Cervical Cancer Treatment in Bulgaria

    Dec 1, 2025, 00:00

  • PCR169 Patient and Caregiver Recommendations for Person-Centered Oncology Clinical Trial Design: A Qualitative Study

    Dec 1, 2025, 00:00

  • EE656 Site of Care Cost-Effectiveness of Axicabtagene Ciloleucel in Relapsed/Refractory Second-Line or Later Large B-cell Lymphoma in the United States: Analyses for Inpatient and Outpatient Infusion Settings

    Dec 1, 2025, 00:00

  • HPR43 Characterizing Medicines Reimbursed Under Managed Access Protocols in Ireland (2006-2025)

    Dec 1, 2025, 00:00

  • HTA262 Overall Survival Adjusted for Subsequent Treatments: A Review of Health Technology Assessments

    Dec 1, 2025, 00:00

  • EE706 The Economic Value of Diagnostic Strategies in Hepatitis D: A Methodological Review of Cost-Effectiveness Models

    Dec 1, 2025, 00:00

  • HSD78 Optimizing Healthcare Access Through Policy Innovation: An Implementation Evaluation Framework for Hepatitis C Elimination Program in Malaysia

    Dec 1, 2025, 00:00

  • CO250 Therapeutic Benefit of Radiotherapy in Uterine Serous Carcinoma (USC): A Real-World Study

    Dec 1, 2025, 00:00

  • EE94 Budget Impact Analysis of Rozanolixizumab for the Treatment of Generalized Myasthenia Gravis (gMG) in Greece

    Dec 1, 2025, 00:00

  • EE97 Budget Impact Analysis of Subcutaneous Ocrelizumab for Relapsing Multiple Sclerosis in Italy: A Hospital Perspective

    Dec 1, 2025, 00:00

  • PCR89 Exploration of the Utility of Linguistic Validation Cognitive Debriefing Interviews in Generating Evidence for Adding or Modifying Source COA Content

    Dec 1, 2025, 00:00

  • HTA312 The 90-Day Ambition: Historical Analysis of 200 NICE Appraisals to Assess Proportion-Achieving Final Guidance Within 90 Days of MHRA Approval

    Dec 1, 2025, 00:00

  • HPR87 Extension of the Mammographic Screening Program in Italy: Cost-Benefit Analysis and Impact of Early Diagnosis in the 45-74 Age Group

    Dec 1, 2025, 00:00

  • MSR188 Single-Agent vs. Multi-Agent RAG for Health Economic Model Replication: A Comparative Evaluation

    Dec 1, 2025, 00:00

  • HSD61 Impact on Prescribing Choice Following the Identification of Preferred Continuous Glucose Monitoring Sensors in the Irish Healthcare Setting

    Dec 1, 2025, 00:00

  • EPH33 Burden of Bloodstream Infections in the United States: Incidence and Healthcare Resource Utilization 2022-2024

    Dec 1, 2025, 00:00

  • RWD118 Leveraging Large-Language Models for Medical Code List Creation: An Example Using the Charlson Comorbidity Index

    Dec 1, 2025, 00:00

  • CO197 Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nirogacestat in Patients With Desmoid Tumors

    Dec 1, 2025, 00:00

  • EE257 Cost-Effectiveness of In-Hospital Motivational Smoking Cessation Counseling and Proactive Referral to Primary Care Follow-up

    Dec 1, 2025, 00:00

  • RWD172 Sex Differences in Characteristics and Treatment Patterns of Patients With Sleep Disorders in South Korea

    Dec 1, 2025, 00:00

  • HTA326 The Phantom Mena How Consultations and Appeals During NICE HST Appraisals Contribute to Delays in Patient Access

    Dec 1, 2025, 00:00

  • HTA296 Scoping the Future: Using NICE Scopes to Inform PICO Prediction for EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • MSR148 Missing Health State Utility Values (HSUV) in NICE Oncology Appraisals: A Systematic Review of Utility Data Reporting and Handling Practices

    Dec 1, 2025, 00:00

  • EE177 Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the First-Line Treatment of Chronic Lymphocytic Leukemia in Brazil

    Dec 1, 2025, 00:00

  • PCR82 Evaluating the Feasibility and Acceptability of a Personalized Endpoint: A Prospective Mixed Methods Study of Inventory-Facilitated Goal Attainment Scaling

    Dec 1, 2025, 00:00

  • RWD116 Leveraging a Multicountry Real-World Data Observatory to Monitor Respiratory Tract Infections and Evaluate Public Health Interventions in Europe

    Dec 1, 2025, 00:00

  • HTA259 One Trial, Two Clocks: Coordinating EMA Assessment and Complementary EU HTA Evidence

    Dec 1, 2025, 00:00

  • HSD38 Economic Burden and Healthcare Resource Utilization of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Germany: A Claims Data Analysis

    Dec 1, 2025, 00:00

  • EE92 Budget Impact Analysis of Obecabtagene Autoleucel for Adults With Relapsed/Refractory B-cell ALL From a US Payer Perspective

    Dec 1, 2025, 00:00

  • EE162 Cost-Effectiveness Analysis of Pembrolizumab in Combination With Enfortumab Vendotin for First-Line Treatment of Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

    Dec 1, 2025, 00:00

  • HPR144 Narrative Review of Total Quality-Adjusted Life Year (QALY) Gains From Oncology Medicines Reimbursed From 2020 To 2025 in Ireland

    Dec 1, 2025, 00:00

  • PT10 An Analysis of Possible Reference Countries for a US Most-Favored Nation Policy and the Associated Impact on the Global Pharmaceutical Industry

    Dec 1, 2025, 00:00

  • EPH166 Mortality in COPD and Cardiovascular Disease Comorbidity: Survival Analysis Using Curated Data From Brazilian Public Healthcare System (SUS)

    Dec 1, 2025, 00:00

  • HTA242 Navigating Evidence Requirements for Joint Clinical Assessment (JCA): Practical Considerations for Systematic Literature Review (SLR) and Indirect Treatment Comparisons (ITCs)

    Dec 1, 2025, 00:00

  • EE187 Cost Savings From Patient Preference-Based Allocation of High-Efficacy Therapies for MS: Evidence From Switzerland

    Dec 1, 2025, 00:00

  • PCR160 Mental Health Benefits of Exercise Variation: Evidence From the 2024 5EU National Health and Wellness Survey

    Dec 1, 2025, 00:00

  • PCR242 The Road Ahead: A Qualitative Study Mapping the Experience of Patients With Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • PT9 Mind the Gap: Understanding the Global Imbalances in Spending for Innovative Medicines

    Dec 1, 2025, 00:00

  • EE197 Cost-Effectiveness Analysis of Entrectinib in First-Line Treatment for NTRK Locally Advanced or Metastatic NSCLC in China

    Dec 1, 2025, 00:00

  • EE265 Cost-Effectiveness of Pegcetacoplan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients With Treatment Failure After C5 Inhibitor Therapy: An Analysis From the Brazilian Public Healthcare System Perspective

    Dec 1, 2025, 00:00

  • HTA254 NICE Has Embraced Single-Arm Trials in Technology Appraisals but Where Is the Guidance?

    Dec 1, 2025, 00:00

  • SA10 Alternative Evidence Generation Approaches for Rare Diseases: Addressing HEOR and Healthcare Decision-Making Challenges

    Dec 1, 2025, 00:00

  • EE329 Digital Health Literacy, Engagement, and the Economics of Health Behavior: Evidence from the US HINTS Survey

    Dec 1, 2025, 00:00

  • HTA330 The Role of Health-Related Quality of Life in German HTA Decisions: An Analysis of G-BA Assessments From 2020-2024

    Dec 1, 2025, 00:00

  • P49 Social and Economic Burden Among Patients With Inherited Retinal Disease: A Nationwide Matched Cohort Study in Sweden 2001-2021

    Dec 1, 2025, 00:00

  • HTA93 Cost-Effectiveness Analysis of Gemcitabine Nabpaclitaxel Combination, Modified FOLFIRINOX, and SIROX As First-Line Therapy for Pancreatic Cancer

    Dec 1, 2025, 00:00

  • EE3 A Budget Impact Analysis of Switching From Von Willebrand Factor/Factor VIII Plasma-Derived Concentrate With 2.4-1 Ratio to the Concentrate With 1-1 Ratio for the Management of Von Willebrand Disease in Qatar

    Dec 1, 2025, 00:00

  • HPR217 Three Systems, One Market? A Comparative Analysis of Medical Device Reimbursement in Germany, Austria, and Switzerland

    Dec 1, 2025, 00:00

  • EE2 A Budget Impact Analysis of Exclusive Human Milk Diet in Very Low Birth Weight Infants in Sheikh Shakhbout Medical City

    Dec 1, 2025, 00:00

  • EE551 Indirect Costs Associated With Pneumococcal Disease: A Global Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA354 Validation of a Natural Language Processing Solution (REALLI) Compared to Manual Review by Physicians of Electronic Health Records (EHR) From Patients With HER2+ Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • EE209 Cost-Effectiveness Analysis of Isavuconazole vs. Liposomal Amphotericin B for the Treatment of Invasive Mucormycosis in Morocco

    Dec 1, 2025, 00:00

  • CO43 Clinical Burden and Transfusion-Related Outcomes in Transfusion-Dependent Thalassemia in the Kingdom of Saudi Arabia and United Arab Emirates

    Dec 1, 2025, 00:00

  • PCR93 Exploring Quality of Life in Duchenne Muscular Dystrophy: Insights From Qualitative Patient and Caregiver Interviews

    Dec 1, 2025, 00:00

  • HPR141 Melatonin Use Among Children and Adolescents: A Finnish Nationwide Drug Utilization Study

    Dec 1, 2025, 00:00

  • CO215 Roflumilast Foam 0.3% in Patients With Psoriasis of the Scalp and Body: Improvements in Patient-Reported Outcomes and Quality of Life

    Dec 1, 2025, 00:00

  • PCR239 The Rapid Involvement of Patients and the Public in Evidence Synthesis (RIPPLES) Framework: Development and Guidance

    Dec 1, 2025, 00:00

  • EE242 Cost-Effectiveness of Connected Injection Device for Pediatric Growth Hormone Deficiency in Spain: A Scenario-Based Microsimulation Analysis Using Real-World Data

    Dec 1, 2025, 00:00

  • EE616 Pricing Implications of Subcutaneous Reformulations Following Intravenous Launches: A Multicountry Analysis

    Dec 1, 2025, 00:00

  • MSR6 A Multistate Framework for Analyzing Outcomes in Diffuse Large B-cell Lymphoma With Autologous Hematopoietic Stem Cell Transplant

    Dec 1, 2025, 00:00

  • EE485 HDX vs. HDF in End-Stage Kidney Disease: Cost-Minimization Study in Saudi Arabia

    Dec 1, 2025, 00:00

  • MSR195 The AI-in-RWE Transparency (AIRT) Checklist: Essential and Desirable Standards for AI-Enhanced Real-World Evidence

    Dec 1, 2025, 00:00

  • HPR202 The Impact of Annual Price Revision Based on External Reference Pricing on Medicines Between 2012 and 2023 in Portugal

    Dec 1, 2025, 00:00

  • CO162 Matching-Adjusted Indirect Comparison Between Garadacimab and Donidalorsen for Long-Term Prophylaxis in Hereditary Angioedema

    Dec 1, 2025, 00:00

  • EPH231 The Cost of Complacency: Projecting the Burden of HIV Care in Eight European Countries

    Dec 1, 2025, 00:00

  • EE527 Impact of CFTR Modulator Initiation on Direct Medical Costs for People With Cystic Fibrosis

    Dec 1, 2025, 00:00

  • EPH48 Comorbidities and Comedication Among Individuals in Treatment for ADHD: A Danish Nationwide Study

    Dec 1, 2025, 00:00

  • EE595 Obstructive Sleep Apnea (OSA) Phenotypes and the Personalized Impact of Positive Airway Pressure (PAP) Therapy on Healthcare Resource Use

    Dec 1, 2025, 00:00

  • EPH131 Identifying CKD As a Key Driver of CVD Deaths

    Dec 1, 2025, 00:00

  • EE28 A Real-World Retrospective Cohort Study Characterizing Healthcare Resource Utilization and Costs Among Patients With MMN in the United States

    Dec 1, 2025, 00:00

  • EE462 Feasibility Evaluation of Claims Database: Best Practices and Case Study for a Comparative Analysis of Robotic-Assisted Colorectal Surgery in Germany

    Dec 1, 2025, 00:00

  • EE315 Cost Utility of Subcutaneous Methotrexate As a Second-Line Treatment for Moderate to Severe Rheumatoid Arthritis in the UK

    Dec 1, 2025, 00:00

  • EPH18 Are Anti-Obesity Drugs Life-Saving or Lifestyle Medicines? Reframing the Policy and Economic Debate

    Dec 1, 2025, 00:00

  • HTA195 Impact of the Societal Perspective on HTA Decision Making in Rare Diseases

    Dec 1, 2025, 00:00

  • CO182 Postmarketing Safety Analysis of Nebivolol in Real-World Settings Using Bioinformatics and Disproportionality Analysis With FDA Adverse Event Reporting System (FAERS) Data

    Dec 1, 2025, 00:00

  • MSR121 How Does the Source of Transition Probabilities Influence Natural History Simulation and Economic Evaluation in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?

    Dec 1, 2025, 00:00

  • EPH182 Population-Level Impact of T-DM1 Use for HER2-Positive Early Breast Cancer According to National Clinical Practice Guidelines in Sweden

    Dec 1, 2025, 00:00

  • MT13 Defining Decision-Making Criteria for Glaucoma Surgery in Non-Refractory, Moderate to Severe Open-Angle Glaucoma: A Stakeholder Analysis Across Multiple Countries with Distinct Payer Archetypes to Support a Multi-Criteria Decision Anal ...

    Dec 1, 2025, 00:00

  • EE582 Model Behavior: A Health Economics Checklist for Sales Models

    Dec 1, 2025, 00:00

  • P31 Comparative Performance of the EQ-5D-5L and PROMIS-10 in the Elderly: Data From the EQ-DAPHNIE Project in Five Countries

    Dec 1, 2025, 00:00

  • EPH143 Incidence of Neutropenia Adverse Events Identified in Electronic Healthcare Records Among Initiators of CDK4/6 Inhibitors With Advanced Breast Cancer in the UK

    Dec 1, 2025, 00:00

  • CO71 Development of a New, Adaptable Patient-Reported Outcome Measure of Treatment Satisfaction

    Dec 1, 2025, 00:00

  • EE518 Healthcare Resource Utilization in Patients With Non-Small Cell Lung Cancer (NSCLC) and Epidermal Growth Factor Receptor Mutation (eGFRm): A Retrospective Cohort Study in a Portuguese Comprehensive Cancer Center

    Dec 1, 2025, 00:00

  • PT35 Cost-Effectiveness Analysis of Ribociclib Plus Endocrine Therapy for the Treatment of HR/HER2 Early Breast Cancer in Greece

    Dec 1, 2025, 00:00

  • EE680 System-Level Economic Impact of a Combination Influenza-COVID-19 Vaccine vs. Standalone Vaccinations in the United Kingdom

    Dec 1, 2025, 00:00

  • MSR128 Implementing SISAQOL Recommendations: Insights From Cancer Clinical Trials

    Dec 1, 2025, 00:00

  • HTA239 Multicriteria Health Technology Assessments for High-Cost Oncology Drugs in Peru: A Cross-Sectional Study of RENETSA Records 2023-2024

    Dec 1, 2025, 00:00

  • HSD22 Characteristics and Treatment of Prevalent Heart Failure in the US: A Cross-Sectional Analysis of Annual Trends From 2014-2023

    Dec 1, 2025, 00:00

  • HTA148 Fractional Polynomial Survival Models in HTA: An Exploratory Review of Use and Methodological Guidance Across Global Agencies

    Dec 1, 2025, 00:00

  • EE316 Danicopan: A Dominant Option for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Residual Hemolytic Anemia in Spain

    Dec 1, 2025, 00:00

  • MSR191 Survival Extrapolations With and Without Incorporating External Eviden Evaluating the Performance of Bayesian M-Spline Models vs. Parametric Models in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Dec 1, 2025, 00:00

  • EPH256 The Use of Multiple Sleep Medications Is Highly Prevalent

    Dec 1, 2025, 00:00

  • MT24 Health Economic Evaluation Model for Ovarian Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • EPH153 Knowledge and Attitudes Regarding the HPV Vaccine Among Secondary School Students

    Dec 1, 2025, 00:00

  • HSD45 Ethical Implications of the Use of Artificial Intelligence (AI) Based Technologies for Medical Image Classification Systems in Screening: A Qualitative Systematic Review

    Dec 1, 2025, 00:00

  • HTA8 A Long and Winding Road: An Evaluation of NICE HST Appraisals Taking Longer Than Two Years for Guidance Publication

    Dec 1, 2025, 00:00

  • EPH73 Epidemiological Analysis of Colorectal Cancer in Cyprus Amidst the Absence of Organized Screening Programs Data From 2000 to 2020

    Dec 1, 2025, 00:00

  • PCR92 Exploring Knowledge Attitudes and Perspectives on Respiratory Viruses Vaccination Among Older Adults in the US

    Dec 1, 2025, 00:00

  • MSR100 Evaluation of the Use of ChatGPT in Data Extraction for Systematic Literature Reviews: Friend, Foe, or Fiction?

    Dec 1, 2025, 00:00

  • HTA30 An Irish Retrospective Analysis of Oncology Reimbursement Applications Considered by HSE Drugs Group 2022-2024

    Dec 1, 2025, 00:00

  • EPH13 An Exploration of the Incidence Rate of Anxiety and Depression Following a Diagnosis of Rheumatoid Arthritis Using the THIN Dataset

    Dec 1, 2025, 00:00

  • RWD180 The Impact of Socioeconomic and Clinical Factors on Mental Healthcare Expenditure: Enabling Quality Managed Care Decisions

    Dec 1, 2025, 00:00

  • EPH114 Generating Data for Diversity Planning in Breast Cancer: A Multi-Database Validation Study Using US Claims and HER, Population Census, and Cancer Registry Data in the United States

    Dec 1, 2025, 00:00

  • HSD118 Trends in Receipt of Preventive Healthcare Services from 2020-2024: US Electronic Health Records (EHR) Database Analysis of 118 Million Patients

    Dec 1, 2025, 00:00

  • PT27 Synthetic Data Generation vs. Simulated Treatment Comparison: Assessment of the Performance of a Novel Approach for Unanchored Indirect Treatment Comparisons

    Dec 1, 2025, 00:00

  • EE48 An Evaluation of the Cost of Treatment for Low-Back Pain Among Patients Attending Public Healthcare Facilities in Nigeria

    Dec 1, 2025, 00:00

  • EE623 Public Health Impact of Efluelda, a High-Dose Trivalent Influenza Vaccine (TIV-HD) Compared to Standard-Dose Trivalent Inactivated Vaccines (TIV-SD)

    Dec 1, 2025, 00:00

  • EPH203 Real-World Costs of United States Patients With T1 Diabetes, Removing Misdiagnosed Patients, and Compared With Patients With T1D and (T1.5 or T2) Diabetes

    Dec 1, 2025, 00:00

  • MT27 Impact of Companion Diagnostics (CDx) on Reimbursement Outcomes of Breast Cancer and NSCLC Therapies

    Dec 1, 2025, 00:00

  • EE12 A Cost-Effectiveness Evaluation of Blinatumomab Use in the Measurable Residual Disease-Negative Remission State to Treat Adults With Philadelphia-Chromosome–Negative B-cell Acute Lymphoblastic Leukemia in France

    Dec 1, 2025, 00:00

  • EE199 Cost-Effectiveness Analysis of Follow-up Strategies for Localized or Locally Advanced Renal Cell Carcinoma From the UK NHS Perspective

    Dec 1, 2025, 00:00

  • PCR69 Embedding Patient Experience Data (PED) in EU Joint Clinical Assessments: Strategic Imperatives and Evidence Practices

    Dec 1, 2025, 00:00

  • HSD58 How Do Neurologists Perceive the Organization and Functioning of Care in Their Multiple Sclerosis Units?

    Dec 1, 2025, 00:00

  • PCR137 Improving Time to Patient: Insights From the Canadian Cancer Treatment Hackathons

    Dec 1, 2025, 00:00

  • MSR202 The Statistical Abyss: Real-World Evidence for Health Technology Assessment

    Dec 1, 2025, 00:00

  • SA46 Get Real: A How-to Framework on Designing and Implementing a Regulatory and HTA-Grade External Comparator Study

    Dec 1, 2025, 00:00

  • HTA203 Insights on Progress Toward Patient-Centered HTA Through Evaluation of PRO Integration, Value Disconnects, and Policy Change in the EU5

    Dec 1, 2025, 00:00

  • HTA95 Cost-Effectiveness Analysis of RSVpreF Vaccine for RSV Prevention in Older Adults Under Situation of the National Vaccination Program in Taiwan: A Study on Economic and Clinical Advantages

    Dec 1, 2025, 00:00

  • PCR200 Qualitative Trial Interviews to Explore the Experience of Adult and Pediatric Patients Participating in a Pivotal Phase 3 Trial of DTX401 for Glycogen Storage Disease Type Ia

    Dec 1, 2025, 00:00

  • P57 Defining "Value" in Digital Health Interventions: A Triangulated Approach to Model Development

    Dec 1, 2025, 00:00

  • PCR191 Preferences for a Combination Influenza and COVID-19 Vaccine: Results From a Stated-Preference Survey With Consumers in the United States, United Kingdom, and Germany

    Dec 1, 2025, 00:00

  • HPR236 Value of Patient-Reported Outcomes Data in Food and Drug Administration Labeling of Oncology Drugs to Payers in the United States

    Dec 1, 2025, 00:00

  • MSR86 Ensuring Patient Inclusion When Baseline Is Missing: Utilizing Constrained Longitudinal Data Analysis (cLDA) for Patient-Reported Outcomes (PROs)

    Dec 1, 2025, 00:00

  • EE361 Economic Burden of Generalized Myasthenia Gravis (gMG) in Latin America (LA): A Microcosting Analysis of Direct Medical Costs (DMCs)

    Dec 1, 2025, 00:00

  • EE255 Cost-Effectiveness of I-CREATE: An Inpatient Intrinsic Capacity Risk Evaluation Towards Holistic Assessment and Targeted Management of Elderly in Acute Care

    Dec 1, 2025, 00:00

  • EE314 Cost-Utility of Protocoled Practice Nurse-Led Care for Children With Asthma in Primary Care

    Dec 1, 2025, 00:00

  • EE461 Faricimab vs. Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration: A Cost-Utility Analysis in Italy

    Dec 1, 2025, 00:00

  • MSR17 Agentic-AI Analyzer to Chat With Your Excel-Based Cost-Effectiveness Models

    Dec 1, 2025, 00:00

  • HTA372 Will Patient Input Shape EU-Level HTA Assessments? HTA Representative Perspectives on the EU HTA Regulation

    Dec 1, 2025, 00:00

  • MSR85 Empirical Evidence on Impact by Accounting for Cluster Effect Within Patients in Cohort Studies Evaluating Comparative Effectiveness of Dental Treatments: A Meta-Epidemiological Study

    Dec 1, 2025, 00:00

  • HTA347 Unmet Needs in NICE HTAs: Insights From Obesity and Diabetes Submissions

    Dec 1, 2025, 00:00

  • EE580 Microsimulation Model to Estimate the Clinical and Cost Burden of Adverse Events Related to Long-Term Oral Corticosteroid Usage in Autoimmune Diseases in the United States

    Dec 1, 2025, 00:00

  • EE302 Cost-Utility Analysis of Iptacopan for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated With C5 Inhibitor in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • RWD81 Evolving Trends in Patient Demographics and Diagnosis in Gastric Cancer: A Real-World Analysis From US Community Oncology Practices From 2014 to 2024

    Dec 1, 2025, 00:00

  • MSR129 Improving Efficiency in Evidence Synthesis: Performance Assessment of Machine Learning Classifiers for Automated Screening in Systematic Literature Reviews

    Dec 1, 2025, 00:00

  • EPH209 Screening for Chronic Kidney Disease (CKD): A Systematic Review and Meta-Analysis of Trials and Quasi Experimental Studies

    Dec 1, 2025, 00:00

  • MSR152 Natural History of Creutzfeldt-Jakob Disease: A Comparison of Manual vs. Manual Plus AI-Assisted Approaches in Literature Review

    Dec 1, 2025, 00:00

  • PCR58 Development of a Content-Valid Patient-Reported Outcome (PRO) Measure for Adults With Glycogen Storage Disease Type 1a (GSD1a): The GSD1a Symptom Diary-Adult Version

    Dec 1, 2025, 00:00

  • RWD62 Development and Validation of an Automated Cancer Stage Classifier for Real-World Oncology Data Mapped to the OMOP Common Data Model

    Dec 1, 2025, 00:00

  • EPH96 Evidence-Driven Simulated Agents to Train Reinforcement Learning for Personalization in mHealth Interventions

    Dec 1, 2025, 00:00

  • EE540 Impact of Proteinuria and Declining Kidney Function on the Healthcare Resource Utilization and Associated Costs of Patients With IgA Nephropathy: A Retrospective Analysis in the UK and Spain

    Dec 1, 2025, 00:00

  • HTA292 Role of PROs in HTA and Reimbursement Decisions Across UK, Germany, France, Italy, and Spain

    Dec 1, 2025, 00:00

  • RWD53 Decoding Asthma: A Tale of Two Databases

    Dec 1, 2025, 00:00

  • EE592 Multistakeholder Engagement to Codevelop Specifications for Economic Models: The MASH Case Study

    Dec 1, 2025, 00:00

  • RWD94 Healthcare Resource Utilization Associated With Acute Pancreatitis in Patients With Familial Chylomicronemia Syndrome Treated With Olezarsen: A Post Hoc Analysis of Balance Study Data

    Dec 1, 2025, 00:00

  • EE390 Economic Evaluation of the RESET Study Weight Loss Phase: Impact on Event Risk Reduction and Cost-Effectiveness in Type 2 Diabetes Management

    Dec 1, 2025, 00:00

  • HTA82 Comparing HTA Outcomes and Rationale for Decision Making Between Countries With Mature vs. Newly Founded HTA Systems: Evidence From England, France, and Greece

    Dec 1, 2025, 00:00

  • PCR73 Enhancing Patient Engagement in Consensus Development: Global Insights From a Targeted Review of Digital Platforms and Methods

    Dec 1, 2025, 00:00

  • MSR201 The Role of Qualitative Research in Randomized Controlled Trials Involving Drugs and Medical Devices: A Systematic Mapping Review

    Dec 1, 2025, 00:00

  • CO232 Systematic Review of Real-World Data on the Effectiveness and Safety Profiles of First-Line Therapies in Chronic Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • SA26 Current Use of Hereditary Angioedema (HAE) Treatments in Sweden: An Analysis of the National Prescribed Drug Register

    Dec 1, 2025, 00:00

  • HTA298 Similarities and Differences Between the National Institute for Health and Care Excellence (NICE) and European Union Joint Clinical Assessment (EU JCA) Clinical Systematic Literature Review Requirements

    Dec 1, 2025, 00:00

  • EE23 A Model-Based Estimation of Productivity-Adjusted Life Years Due to Depression in Germany

    Dec 1, 2025, 00:00

  • HTA103 Defining Unavoidable Uncertainty in HTA: Towards More Flexible and Adapted Approaches for Promising Treatments

    Dec 1, 2025, 00:00

  • HPR71 Estimating Lost Life-Years and Quality-Adjusted Life-Years of Undertreatment of Patients With Renal Cell Carcinoma and Metastatic Pancreatic Cancer in England

    Dec 1, 2025, 00:00

  • EE755 When Cost-Effectiveness No Longer Counts: Industry Views on the Undermining of HTA Principles in Korea

    Dec 1, 2025, 00:00

  • EPH158 Literature Review on the Economic Impact of Maternal Fetal Infections

    Dec 1, 2025, 00:00

  • EE74 Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective

    Dec 1, 2025, 00:00

  • EPH151 Is Greece on Track to Meet the 90% HPV Vaccine Coverage Rate Target by 2030? A Mathematical Modeling Study

    Dec 1, 2025, 00:00

  • EPH46 Clinical Functional Profile and Neuroimaging in Cerebral Palsy: A Population-Based Study

    Dec 1, 2025, 00:00

  • MSR144 Measuring Health-Related Quality of Life and Food Insecurity in the General Population in Lebanon During the Third Worst Socioeconomic Crisis in History

    Dec 1, 2025, 00:00

  • EE460 Factors Associated With the Highest Costs Among US Adults With Primary Biliary Cholangitis

    Dec 1, 2025, 00:00

  • HPR208 The Landscape of Antibiotic Development and Regulation in the United States and Europe, Alongside Evolving Industry Incentive Strategies

    Dec 1, 2025, 00:00

  • EE384 Economic Evaluation of Sodium Zirconium Cyclosilicate Lokelma for Treating Hyperkalemia in Patients With Heart Failure and/or Chronic Kidney Disease in Egypt

    Dec 1, 2025, 00:00

  • EE188 Cost Trends for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management in Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) Treatment With Axicabtagene Ciloleucel (Axi-cel) in ...

    Dec 1, 2025, 00:00

  • OP1 Bridging the Gap Between AI Principles and Practi A Comparative Evaluation of AI Position Statements and Frameworks for Responsible Use

    Dec 1, 2025, 00:00

  • EE743 Unlocking the Value of RSV Adult Vaccination With Adjuvanted RSVpreF3 Vaccine in Spain: A Return on Investment Analysis Using an Integrated Actuarial Macroeconomic Model

    Dec 1, 2025, 00:00

  • MSR133 Integrating Equity and Efficiency in Health Economic Evaluation: Development of Equity-Informed Methodologies in the French Healthcare Context (INEES Project)

    Dec 1, 2025, 00:00

  • CO151 Indirect Treatment Comparisons in Health Technology Assessment Submissions: A Review and Critique of Best Practice

    Dec 1, 2025, 00:00

  • CO242 The Impact of Network Meta-Analyses on HTA Decisions in Oncology: A Review of NICE Appraisals

    Dec 1, 2025, 00:00

  • RWD112 Landscape of Data Sources for Real-World Observational Studies: Focus on the French Context

    Dec 1, 2025, 00:00

  • EE731 Therapeutic Drug Monitoring and Selective Use of Glucarpidase in High-Dose Methotrexate Therapy: A Cost Analysis From the Algerian Payer Perspective

    Dec 1, 2025, 00:00

  • EE148 Components of the Direct Cost of Topical Treatment for Chronic Wounds in Adults and Elderly: A Systematic Review

    Dec 1, 2025, 00:00

  • EPH52 Cost-Effectiveness Analysis Of The 13-Valent And 20-Valent Pneumococcal Conjugate Vaccine In The Kazakh Adult Population

    Dec 1, 2025, 00:00

  • EE569 Long-Term Impact of Emicizumab in Hemophilia A (HA): Analysis by Inhibitor Status in Three Latin American (LATAM) Countries

    Dec 1, 2025, 00:00

  • MSR84 Empirical Comparison of Four Approaches for Generating Confidence Intervals Around Weighted Trial-Level Correlation

    Dec 1, 2025, 00:00

  • EE232 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among High-Risk Adults in Taiwan

    Dec 1, 2025, 00:00

  • HPR158 Perceived Impact and Actionability of Barriers to Drug Repurposing: Insights From a Multistakeholder Policy Survey

    Dec 1, 2025, 00:00

  • EE693 The Cost-Effectiveness of Imlifidase Idefirix® for Desensitization Treatment of Highly Sensitized Adult Kidney Transplant Patients in Ireland

    Dec 1, 2025, 00:00

  • PCR144 Investigation of the Impact of Hereditary Angioedema (HAE) on Health-Related Quality of Life: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE173 Cost-Effectiveness of WIC Eligibility Extension in Preventing Maternal Postpartum Depression: US Payers’ Perspective

    Dec 1, 2025, 00:00

  • MT31 National Competent Authorities’ Experiences With Early Feasibility Study Assessment: Promoting Dialogue, Supporting Sponsors, and Fostering Shared Learning to Harmonize the EU Framework

    Dec 1, 2025, 00:00

  • RWD85 FLAME: An Open-Source Federated Platform for Deeply Phenotyped and Multimodal Studies at Population Scale

    Dec 1, 2025, 00:00

  • CO231 Systematic Review of Prognostic Factors for Efficacy and Safety Outcomes in CAR-T Cell Therapy for Diffuse Large B-cell Lymphoma

    Dec 1, 2025, 00:00

  • HTA109 Development of a Unique Tool for Assessing the Feasibility of an External Control Arm Study

    Dec 1, 2025, 00:00

  • EE738 Treatment With Semaglutide Reduces the Complication Costs Among Type 2 Diabetes Patients With CKD in China: A Short-Term Cost Analysis Based on the FLOW Trial

    Dec 1, 2025, 00:00

  • EE709 The Growing Importance of Reserve Antibiotics in Organ Transplant Care and the Role of Timely Appropriate Antibiotic Treatment to Preserve the Benefits of Prior Health Investments

    Dec 1, 2025, 00:00

  • RWD165 Real-World Treatment Patterns of Locally Advanced and Metastatic Urothelial Cancer (la/MUC) in Fran A Secondary Database Analysis

    Dec 1, 2025, 00:00

  • P35 Incorporating Environmental Impacts Into Budget Impact Models: A Case Study of CAR-T Therapies in France

    Dec 1, 2025, 00:00

  • HTA205 Integrating Health Equity Into Health Technology Assessment: A Scoping Review

    Dec 1, 2025, 00:00

  • CO61 Comparison of Bispecific T-cell Engager Antibodies and CAR-T Therapies for Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • HTA180 How Societal Is Sweden? A Study of Inclusion of Societal Costs in Swedish Reimbursement Decisions

    Dec 1, 2025, 00:00

  • EE367 Economic Burden of the Adverse Events During Treatment of Metastatic Breast Cancer (mBC) HR(+) HER2(-) Patients in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • PCR205 Real-World Drivers of Adherence in Obesity Highlight the Need for Patient-Centered Interventions

    Dec 1, 2025, 00:00

  • HPR233 Using Expert Consensus to Expand Access in Rare Disease Populations: Generating Evidence for Patients With Permanently Ventilated Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • HPR30 Assessing the Potential Impact of NICE’s Updated HST Routing Criteria on Ultraorphan Drugs

    Dec 1, 2025, 00:00

  • HTA26 Advancing Patient Involvement in Health Technology Assessment

    Dec 1, 2025, 00:00

  • HTA107 Development and Validation of a Machine Learning Model for Predicting French HAS ASMR Ratings Using Product and Disease Characteristics

    Dec 1, 2025, 00:00

  • HPR224 Trends and Scope of Japan’s Across-the-Board Pharmaceutical Price Revisions in FY2021-25

    Dec 1, 2025, 00:00

  • HPR192 Ten Years of Portugal’s HTA System Through Stakeholder Eyes: Reflections and Future Priorities

    Dec 1, 2025, 00:00

  • EE65 Assessing Time Tradeoff Utilities in Health States of Organic Hypogonadotropic Hypogonadism: A Pilot Study in Brazil

    Dec 1, 2025, 00:00

  • EPH168 Mutagenicity of Imazalil, Pyrimethanil, and Thiabendazole With and Without Citrus Oil

    Dec 1, 2025, 00:00

  • EE233 Cost-Effectiveness of Adjuvant Alectinib vs. Platinum-Based Chemotherapy in Resected Stage IB-IIIA ALK-Positive NSCLC: A French Health Economic Evaluation

    Dec 1, 2025, 00:00

  • RWD113 Landscape of Natural Language Processing (NLP) Capabilities at Clinical Sites: Insights From a Real-World (RW) Gastric Cancer (GC) Study

    Dec 1, 2025, 00:00

  • HTA14 A Review of NICE Technology Appraisals in Oncology Including Economic Evaluations With Time-Varying Network Meta-Analysis

    Dec 1, 2025, 00:00

  • HTA208 Integrating Real-World Evidence for Advanced Therapies in Inflammatory Bowel Disease Into Reimbursement Submissions: Insights and Considerations From the UK

    Dec 1, 2025, 00:00

  • MSR48 Bootstrap Methods for Confidence Interval Estimation in Small Samples: Implications for Health Economics

    Dec 1, 2025, 00:00

  • HTA145 Exploring Methodologies for Defining and Modeling Cure in Melanoma: Impacts on Estimating Cure Metrics

    Dec 1, 2025, 00:00

  • HPR212 Extent and Causes of the Collapse in the Registration of Innovative Medications in Lebanon: A Mixed-Methods Analysis

    Dec 1, 2025, 00:00

  • EE342 Does Modeling Adherence Matter? Insights From Prior NICE Appraisals

    Dec 1, 2025, 00:00

  • HSD82 Patient Blood Management Efficiency in Patients Subject to Orthopedic and Oncologic Elective Surgery

    Dec 1, 2025, 00:00

  • EE84 Budget Impact Analysis of Eplerenone For the Management of Heart Failure With Reduced Ejection Fraction (HFrEF) in Italy

    Dec 1, 2025, 00:00

  • CO152 Inefficiencies of Off-Label Therapy in the Prevention of Generalized Pustular Psoriasis (GPP) Flares: Real-World Evidence From Europe

    Dec 1, 2025, 00:00

  • HPR10 A Strategic National Framework for Managed Entry Agreements to Access Innovative and Breakthrough Medications in Saudi Arabia

    Dec 1, 2025, 00:00

  • PCR209 Relevance of Quality Indicators for Supporting Patients’ Choice of Hospitals: An Online Survey

    Dec 1, 2025, 00:00

  • EE70 Avacopan in the Treatment of ANCA-Associated Vasculitis: A Cost-Utility Analysis in Portugal

    Dec 1, 2025, 00:00

  • EE610 Population Impact of Performing BRCA1/2 Testing to Guide Metastatic Castration-Resistant Prostate Cancer Treatment in Spain

    Dec 1, 2025, 00:00

  • SA38 Enhancing Targeted Literature Reviews (TLRs) with Artificial Intelligence (AI): A Methodological Approach for Conducting Efficient Targeted Searches

    Dec 1, 2025, 00:00

  • EE446 Evaluating the Performance of an Artificial Intelligence A-Powered Tool for Assessing Quality of Published Economic Evaluations: A Comparison With Human Reviewers Using the Drummond Checklist

    Dec 1, 2025, 00:00

  • SA43 From Methods to Decisions: A Transparent Framework for Population-Adjusted Treatment Comparisons

    Dec 1, 2025, 00:00

  • HTA373 Worth Their Weight? Cost-Effectiveness and Access Decisions for GLP-1 and GIP/GLP-1 Therapies

    Dec 1, 2025, 00:00

  • EE189 Cost Utility Analysis of a Digital Peer Navigation Program for Men With Prostate Cancer

    Dec 1, 2025, 00:00

  • HPR162 Predicting the Maximum Fair Price (MFP) From Medicare Negotiations

    Dec 1, 2025, 00:00

  • HTA248 Navigating Reimbursement Challenges for Pharmacological Interventions in Celiac Disease: Lessons From Analogous Conditions

    Dec 1, 2025, 00:00

  • EE219 Cost-Effectiveness Analysis of Secukinumab for Moderate to Severe Hidradenitis Suppurativa in Portugal

    Dec 1, 2025, 00:00

  • CO148 Incidence of Treatment-Related Adverse Events From Immune Checkpoint Inhibitors: A Meta-Analysis of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • HTA119 Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments

    Dec 1, 2025, 00:00

  • EE510 Healthcare Resource Utilization Among Adults With Pneumococcal Disease in England 2017-2022: A Retrospective Database Analysis

    Dec 1, 2025, 00:00

  • MSR174 Psychometric Evaluation of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire Item-10 (Physical Fatigue) and Idiopathic Thrombocytopenic Purpura Bleeding Scale Using LUNA 3 Phase 3 Trial Data

    Dec 1, 2025, 00:00

  • MSR196 The AI-Only Workflow: Model and Report Adaptation Without Human Setup

    Dec 1, 2025, 00:00

  • MSR225 Win Ratio in the Presence of Censored Data: Can Probabilistic Variants Improve Robustness?

    Dec 1, 2025, 00:00

  • MSR177 Qualitative Analysis of Results From a Delphi Study to Formalize a Treatment Protocol for Children With Early Diagnosed Duchenne Muscular Disease (DMD) Using Giles®, an Artificial Intelligence Agent for Healthcare Research

    Dec 1, 2025, 00:00

  • HPR229 Unintended Consequences of MFN Pricing: Global Access Risks and Revenue Impact

    Dec 1, 2025, 00:00

  • EE553 Informing the Sustainable Development of Novel Therapies Using Value-Based Real Options Analysis

    Dec 1, 2025, 00:00

  • EE408 Embracing the Long-Term in Disruptive Health Innovations: A Strategic Necessity or a Necessary Evil? Cost Utility of Langerhans Islet Grafting in Unstable Type 1 Diabetes

    Dec 1, 2025, 00:00

  • HTA218 Lessons Learnt From PICO Exercise Developed by the Joint Clinical Assessment Subgroup for Etranacogene Dezaparvovec

    Dec 1, 2025, 00:00

  • HPR142 Mind the Gap: Exploring Variation in Guidelines for Indirect Treatment Comparison (ITC) Across Europe

    Dec 1, 2025, 00:00

  • EE362 Economic Burden of Pneumococcal Disease—Impact of Age and Underlying Medical Conditions

    Dec 1, 2025, 00:00

  • CO237 The Clinical Burden of Fractures in Osteogenesis Imperfecta: A Systematic Review

    Dec 1, 2025, 00:00

  • EE237 Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine (RSVpreF) Among Older Adults in Ireland

    Dec 1, 2025, 00:00

  • HTA71 Challenges in PICO Definition for HTDs: Lessons From Durvalumab Exercise

    Dec 1, 2025, 00:00

  • RWD107 Institutional Trends and Healthcare Resource Utilization in Real-World NMIBC and MIBC Treatment in Germany

    Dec 1, 2025, 00:00

  • RWD154 Real-World Evidence in European Orphan Drug Submissions and the Impact on Reimbursement Success

    Dec 1, 2025, 00:00

  • HTA173 Health Technology Assessment (HTA) Systems and Risk Identification Strategies: A Comparative Analysis Across Western European Countries, Canada, and Australia

    Dec 1, 2025, 00:00

  • RWD22 Assessment of Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland

    Dec 1, 2025, 00:00

  • HPR210 The New Discount on Combination Drug Therapies in Germany: First Numbers and Assessment From a Payor Perspective

    Dec 1, 2025, 00:00

  • MSR126 Identifying Risk Profiles for Early Treatment Discontinuation in Geographic Atrophy Using Machine Learning and SHAP Clustering

    Dec 1, 2025, 00:00

  • EE34 A Systematic Literature Review on Costs and Healthcare Resource Utilization in Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • EPH220 Studying Paternal Drug Exposures and Offspring Outcomes: A Feasibility Assessment of 11 Large European Databases

    Dec 1, 2025, 00:00

  • CO20 Association Between ALK Tyrosine Kinase Inhibitor and the Risk of Interstitial Lung Disease and Pneumonitis in Non-Small Cell Lung Cancer Patients: A Systematic Review

    Dec 1, 2025, 00:00

  • EE542 Impact of SGLT2-Inhibitor Uptake in CKD Management in Denmark: A Decision Economic Model

    Dec 1, 2025, 00:00

  • P46 Eliciting Preferences for Combination Vaccines Protecting Against Multiple Respiratory Viruses: A Cross-Sectional Discrete Choice Experiment of Adults Aged 50 in the US

    Dec 1, 2025, 00:00

  • HSD52 From Agricultural Waste to Clinical Value: An Economic and Operational Analysis of Paddy Straw-Based Utensils in Malaysian Hospital

    Dec 1, 2025, 00:00

  • EPH206 Real-World Uptake of SGLT2i Usage in Patients With Chronic Kidney Disease or Heart Failure: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • EE259 Cost-Effectiveness of Minocycline Intravenous for the Treatment of Serious Infections Due to Multidrug-Resistant Acinetobacter baumannii in Jordan

    Dec 1, 2025, 00:00

  • MSR141 Machine Learning for Missing Data Imputation in Healthcare Research: A Systematic Review of Methods and Applications

    Dec 1, 2025, 00:00

  • HTA52 Barriers to Reimbursement: Characteristics of Unfunded Medicines in Ireland (2006-2021)

    Dec 1, 2025, 00:00

  • EE185 Cost per Responder Analysis of Teclistamab Compared to Real-World Physician’s Choice of Carfilzomib and/or Pomalidomide-Based Regimens for Triple-Class Exposed Patients With Refractory/Relapsed Multiple Myeloma

    Dec 1, 2025, 00:00

  • HSD17 Burden of Healthcare Waste for European Hospitals: Findings From an AI-Based Literature Research

    Dec 1, 2025, 00:00

  • HPR132 Leveling the Field: How the MFN Could Transform Drug Pricing

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • MSR47 BHM and BHM-Based Extrapolations in an HTA Framework

    Dec 1, 2025, 00:00

  • PCR244 The Use of Patient-Reported Experience Measures in Adults With Obstructive Sleep Apnea: A Systematic Evidence Review

    Dec 1, 2025, 00:00

  • EE31 A Review of Indirect Costs Within Economic Appraisals in France

    Dec 1, 2025, 00:00

  • HTA49 Associations of Product-Specific and Clinical Evidence Quality Characteristics With Health Technology Assessment Outcomes: A Quantitative Assessment of Appraisals for Drugs for Rare Diseases in England and Germany

    Dec 1, 2025, 00:00

  • EE50 Analysis of Social and Economic Burden of Type 1 Diabetes Care in Italy

    Dec 1, 2025, 00:00

  • EPH280 Years of Life Lost and Productivity TB1 SY2 Costs Due to Premature Cancer-Related Mortality in Morocco

    Dec 1, 2025, 00:00

  • CO260 Using Natural Language Processing to Identify Sequencing Patterns in Advanced Urothelial Carcinoma: A Real-World Observational Study

    Dec 1, 2025, 00:00

  • EE520 How Can Intravitreal Aflibercept 8 mg Impact Treatment Burden and Costs in European Patients With Diabetic Macular Edema? From Clinical Trials to Clinical Practice

    Dec 1, 2025, 00:00

  • CO40 Characterization of the Distribution of Body Mass Index in Portuguese People With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • HPR190 Staying Competitive in a Crowded Vaccine Market: Is There Room for a Third or Fourth Entrant in the Same Disease Area?

    Dec 1, 2025, 00:00

  • RWD143 Real-World Healthcare Resource Utilization and Related Costs Associated With Lung Cancer in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • Methodological Challenges With Conducting Health Economic Evaluations in the Critical-Care Context

    Dec 1, 2025, 00:00

  • HPR119 Implementing Coverage With Evidence Development for Medicines With Uncertain Clinical Benefit: Insights From the Netherlands

    Dec 1, 2025, 00:00

  • Table of Contents

    Dec 1, 2025, 00:00

  • EE249 Cost-Effectiveness of Etrasimod, Ozanimod, and Adalimumab Compared to Infliximab in Treatment-Naive Patients With Moderate to Severe Ulcerative Colitis

    Dec 1, 2025, 00:00

  • EE503 Healthcare Resource Use Among Patients With Chronic Rhinosinusitis With Nasal Polyps in the United Kingdom: Results of an Expert Elicitation Survey

    Dec 1, 2025, 00:00

  • HPR34 Barriers and Policy Solutions in Off-Patent Drug Repurposing: A Full-Life-Cycle Perspective

    Dec 1, 2025, 00:00

  • EE139 Comparative Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole for the Treatment of Invasive Aspergillosis in Algerian Hospital Setting

    Dec 1, 2025, 00:00

  • EE711 The Impact of Adherence on the Value Assessment of Cardiovascular Interventions: A Systematic Literature Review of Economic Evaluations

    Dec 1, 2025, 00:00

  • EE146 Comparative Analysis of Different Crown Materials for Dental Prosthesis From Budget in Wartime in Ukraine

    Dec 1, 2025, 00:00

  • RWD68 Economic and Clinical Burden of MACE-Related Rehospitalizations in Patients With Obesity: A Real-World Study Based on Italian Healthcare Data

    Dec 1, 2025, 00:00

  • PCR79 Evaluating GenAI vs. Human Screenshot Review Outputs in eCOA Localization: Does AI Hold the Key to Improved Feedback?

    Dec 1, 2025, 00:00

  • HTA33 Analysis of the Implementation of Additive PICOs in a European Joint Health Technology Assessment Implications of EUHTA for Pharma: A Qualitative Exploration

    Dec 1, 2025, 00:00

  • EPH19 Artificial Intelligence in Evidence Synthesis: A Systematic Review and Meta-Analysis of Emerging Biologics for Improving Skeletal Health in Osteogenesis Imperfecta

    Dec 1, 2025, 00:00

  • EE576 Medium vs. Low Citrate Concentration in Continuous Kidney Replacement Therapy: Positive Budget Impact Through Total Cost of Ownership Assessment

    Dec 1, 2025, 00:00

  • HTA201 Influence of NICE Real-World Evidence Framework on HTA Submissions: Sensitivity Analyses in Real-World External Control Arm Studies

    Dec 1, 2025, 00:00

  • CO85 Effectiveness of Inclisiran and Evolocumab in LDL-C Goal Attainment: A Hybrid Decision Tree-Markov Model Analysis

    Dec 1, 2025, 00:00

  • EE585 Modeling the Clinical and Economic Impact of DPP-4 Inhibitors in Uncontrolled T2D

    Dec 1, 2025, 00:00

  • PT13 Mapping the Measurement Gap: Patient-Reported Outcomes Across the Obesity Care Continuum in the GLP-1 Era

    Dec 1, 2025, 00:00

  • HTA78 Comparative Analysis of Reimbursement Landscapes: Advantages and Challenges of Bispecifics vs. CAR-T Therapies

    Dec 1, 2025, 00:00

  • HTA345 Uncertainty About How to Translate JCA Into National HTA Submissions (EU-4 and Poland): A Systematic Comparison From an Industry Perspective

    Dec 1, 2025, 00:00

  • EE46 An Economic Evaluation of Risankizumab vs. Adalimumab in Moderate to Severe Plaque Psoriasis Adult Patients in Egypt

    Dec 1, 2025, 00:00

  • EE226 Cost-Effectiveness and Impact of Nirmatrelvir/Ritonavir in Reducing Hospitalizations Among Elderly COVID-19 Patients in Sweden

    Dec 1, 2025, 00:00

  • MSR209 Understanding Drivers on Healthcare Resource Utilization Costs Among People Living With Obesity in UK Clinical Practice

    Dec 1, 2025, 00:00

  • HTA96 Cost-Effectiveness Assessment of Orphan Drugs in Fran Key Insights from CEESP Reviews (2021-2024)

    Dec 1, 2025, 00:00

  • EE317 Danicopan in Addition to the Component 5 Inhibitor C5i Ravulizumab for the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Residual Hemolytic Anemia in Gree A Cost Utility Analysis

    Dec 1, 2025, 00:00

  • HPR13 Acceptance of Clinical Studies Conducted in Nonus Settings by the FDA Based on the Analysis of Selected Novel Drug Approvals

    Dec 1, 2025, 00:00

  • EE669 Spillover Effect in Health Utility Values: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR1 A Comparison of Methods for Missing Covariates in a Meta-Regression Using Data From a Systematic Review on Oral Epithelial Dysplasia

    Dec 1, 2025, 00:00

  • MSR52 Can Generative AI Automate Health Economic Model Verification?

    Dec 1, 2025, 00:00

  • EE589 Modeling the Healthcare Burden of Oral Corticosteroid Use in Mexico

    Dec 1, 2025, 00:00

  • HTA302 Statistical Analysis of Health Technology Assessment Outcomes in Oncology: An Analysis of Key Clinical Value Drivers in Germany and France

    Dec 1, 2025, 00:00

  • PCR263 Valuing Health States When Transitioning From Stage 2 to Stage 3 Type 1 Diabetes in a Sample of the General Population in the United Kingdom

    Dec 1, 2025, 00:00

  • HPR55 Digital Twins: Hype or Hope for Better Health Outcomes

    Dec 1, 2025, 00:00

  • EE40 Adherence to Guidelines for the Treatment of Diabetes With Modern Antidiabetic Drugs in the Czech Republic: Clinical and Economic Impacts

    Dec 1, 2025, 00:00

  • EE600 Optimizing Colorectal Cancer Screening in the Czech Republic: Cost-Effectiveness of Lowering the Starting Age to 45 and Introducing an Upper Limit

    Dec 1, 2025, 00:00

  • HPR88 External Reference Pricing (ERP) Availability vs. Reimbursement Timelines in Poland and Other European Countries: The Analysis of EURIPID Database

    Dec 1, 2025, 00:00

  • HTA362 What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques

    Dec 1, 2025, 00:00

  • RWD32 Characterizing Comorbidities and Co-Occurring Conditions in Adults with Generalized Anxiety Disorder in the United States

    Dec 1, 2025, 00:00

  • EE121 Cardiovascular Disease Risk-Reducing Strategies in Qatari Diabetes Patients: A Cost-Effectiveness Study

    Dec 1, 2025, 00:00

  • EPH82 Epidemiology of Diabetes Mellitus in Pregnancy in Hungary: Trends and Future Projections

    Dec 1, 2025, 00:00

  • HSD67 Knowledge and Practices Regarding Expired Medications Among Saudi Citizens

    Dec 1, 2025, 00:00

  • MSR190 Structured Expert Elicitation for Survival Outcomes: Insights From NICE Technical Support Document 26

    Dec 1, 2025, 00:00

  • HPR60 Diverging Impacts of Evergreening and Biosimilars on Trastuzumab Utilization and Costs in South Korea: Implications for Sustainable Access and Market Competition

    Dec 1, 2025, 00:00

  • EE574 Measures for Integrating Carbon Footprints Into Economic Evaluations: A Targeted Review of Environmental and Economic Metrics

    Dec 1, 2025, 00:00

  • HTA24 Adoption and Evidence Generation in NICE Early Value Assessments (EVA) for Medtech: Trends Across 2023-2025

    Dec 1, 2025, 00:00

  • EE684 Technical Validation of Health Economic Models: Is There a Gold Standard? Assessment and Refinement of Current Checklist Tools

    Dec 1, 2025, 00:00

  • EE349 Economic and Antibiotic Benefits of Vonoprazan-Based Regimens for First-Line Helicobacter Pylori Eradication in China

    Dec 1, 2025, 00:00

  • MT9 Clinical Outcomes of Early Diagnosis of Infections of Sterile Body Fluids: A Living Systematic Review and Meta Analysis

    Dec 1, 2025, 00:00

  • EPH130 Hospitalizations for Myasthenia Gravis: Pre- and Post-COVID Trends

    Dec 1, 2025, 00:00

  • EE707 The Economic Value of Self-Administered Subcutaneous Immunoglobulin G (SCIg) in Canada: A Scoping Review

    Dec 1, 2025, 00:00

  • EE176 Cost Of Adverse Events Associates With the Management of Invasive Mold Disease With Isavuconazole Compared With Voriconazole in Spain

    Dec 1, 2025, 00:00

  • EPH216 Social Inequality in the Uptake of Varicella Vaccination: A Danish Nationwide Observational Study

    Dec 1, 2025, 00:00

  • HTA361 What Did Time Reveal Evaluating the Accuracy of Parametric Model Predictions Against Long-Term Observed Data for Larotrectinib?

    Dec 1, 2025, 00:00

  • RWD99 Identification of Real-World Data to Study HAE Unmet Need: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE67 Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection

    Dec 1, 2025, 00:00

  • PCR190 Predicting Self-Efficacy in Managing Type 2 Diabetes: Results From a Low-Income, Less Educated Community of Quetta City, Pakistan

    Dec 1, 2025, 00:00

  • CO18 Assessment of Oncology Analog HTA Outcomes and Evidence Needs in France and Germany

    Dec 1, 2025, 00:00

  • HTA315 The Elusive PICO: Assessing Prediction in Joint Clinical Assessments (JCA): A Case Study in Soft Tissue Sarcoma (STS)

    Dec 1, 2025, 00:00

  • EPH81 Epidemiology of Breast Cancer in France

    Dec 1, 2025, 00:00

  • PCR81 Evaluating Patient Preferences for Clinical Trial Endpoints in Early Stage Cancer: A Discrete Choice Experiment in Canada

    Dec 1, 2025, 00:00

  • RWD178 Systematic Review of Effectiveness of SGLT2 Inhibitors in Patients With Type 2 Diabetes With Focus on Glucose Levels, Cardiovascular Events, and Renal Function

    Dec 1, 2025, 00:00

  • HTA43 Artificial Intelligence-Based Population, Intervention, Comparator, and Outcome (PICO) Prediction for European Union (EU) Joint Clinical Assessment (JCA)

    Dec 1, 2025, 00:00

  • EE8 A Cost per Responder Analysis of Lipid-Lowering Therapies in Patients With Established Atherosclerotic Cardiovascular Disease in Italy

    Dec 1, 2025, 00:00

  • EE638 Real-World Healthcare Resource Utilization in Individuals With Phenylketonuria: A Retrospective Observational Study in the United States

    Dec 1, 2025, 00:00

  • EPH193 Prevalence of Post-Traumatic Stress Disorder Among Ambulance Officers During the COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • HTA309 Systematic Review of Value Assessment Frameworks for Digital Health Interventions: Toward a Multidimensional Evaluation Approach

    Dec 1, 2025, 00:00

  • HPR95 Financial Impact of EU MDR Complian A Cost-Mapping Assessment for Manufacturers

    Dec 1, 2025, 00:00

  • EE368 Economic Burden Utilities and Cost-Effectiveness of the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HTA164 Get JCA-Ready: Mastering PROs for Market Access Success

    Dec 1, 2025, 00:00

  • SA103 What Makes a Medicine Innovative? A Literature Review of Evaluation Frameworks

    Dec 1, 2025, 00:00

  • RWD161 Real-World Insights Into Prostate Cancer Management Using Electronic Health Record-Derived Data From the UK

    Dec 1, 2025, 00:00

  • MSR51 Can an Ensemble Machine-Learning Approach Outperform Traditional Models While Enhancing Accuracy, Fairness, and Interpretability in Clinical Risk Prediction?

    Dec 1, 2025, 00:00

  • PCR133 Impact of Transfusion-Dependent Thalassemia on Adult Patients’ Health-Related Quality of Life and Work Productivity in the Kingdom of Saudi Arabia and United Arab Emirates

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4 (current)
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »